Gilder Gagnon Howe & Co’s ACELYRIN SLRN Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio SLRN Stock Details SLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-28,483	Closed	-$595K	–	301
2023 Q2	$595K	Buy	+28,483	New	+$583K	0.01%	243

Other funds holding SLRN

ACMC

AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Gilder Gagnon Howe & Co's SLRN Position: Q3 2023 in Review

Gilder Gagnon Howe & Co sold out of ACELYRIN (SLRN) in Q3 2023, closing a stake of 28,483 shares — an estimated $595K sold.

Gilder Gagnon Howe & Co first reported a position in SLRN in Q2 2023 and held it in 1 quarter. The position peaked at $595K in Q2 2023. 101 funds tracked by Wall St. Rank hold SLRN as of Q3 2023.

Gilder Gagnon Howe & Co reported no remaining ACELYRIN position as of Q3 2023 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 28,483 ACELYRIN shares in Q3 2023, an estimated $595K.
Gilder Gagnon Howe & Co first reported a position in ACELYRIN in Q2 2023 and held it in 1 quarter.
Gilder Gagnon Howe & Co's ACELYRIN position peaked at $595K in Q2 2023.
101 funds tracked by Wall St. Rank held ACELYRIN as of Q3 2023.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2023, filed 14 Nov 2023.